Seres Therapeutics

📍 Cambridge, United States🗓 Founded 2010👥 168 employees💰 Last funded Sep 2025
Biotechnology Research🌐 serestherapeutics.com
Website LinkedIn
Seres Therapeutics is a commercial-stage company developing novel microbiome therapeutics for serious diseases. Our lead program, VOWST™, obtained U.S. FDA approval in April 2023 as the first orally administered microbiota-based therapeutic to prevent recurrence of C. difficile infection (CDI) in adults following antibacterial treatment for recurrent CDI and is being commercialized in collaboration with Nestlé Health Science. We are evaluating SER-155 in a Phase 1b study in patients receiving allogeneic hematopoietic stem cell transplantation to reduce incidences of gastrointestinal infections, bloodstream infections, and graft-versus-host disease as well as additional preclinical stage programs targeting Infection Protection in medically compromised patients. We are also conducting research to inform further development of microbiome therapeutics for ulcerative colitis. For more information, please visit http://www.serestherapeutics.com/ .
3
Total investors
2
Early stage
0
Mid stage
0
Late stage
2010
Founded

Investors

3 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
3
Investor activity2010–2025 · investors recorded per year
201012011120251
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Seres Therapeutics?
Seres Therapeutics has 3 investors on record on gritt.io, including 2 early-stage backers.
When did Seres Therapeutics last raise funding?
The most recent investment in Seres Therapeutics recorded on gritt.io was in September 2025.
When was Seres Therapeutics founded?
Seres Therapeutics was founded in 2010.
What industry is Seres Therapeutics in?
Seres Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Seres Therapeutics based?
Seres Therapeutics is headquartered in Cambridge, United States.